DAVOS OBSERVER

THE WALL STREET JOURNAL

The Fed’s apparent desire to push on with tightening policy may give emerging markets a pause. But if global growth continues, then a pause is all it should be.
The failure of a high-profile clinical trial to treat Alzheimer’s disease means that the biotech market is about to get a big test. But Axovant’s stock meltdown is unlikely to spread.
Nestlé has published a margin target, but not the aggressive one demanded by activist investor Dan Loeb of Third Point. And it doesn’t make the company’s shares look much less expensive.
Chinese e-commerce giant Alibaba’s decision to consolidate earnings from its logistics subsidiary Cainiao may improve delivery—but at a cost.
Oil is back in a bull market, but China is slowing down. Oftentimes, those two things aren’t compatible.
The death care business has boomed lately and is in a demographic groove, but consider recent loser StoneMor instead of industry leader Service Corp.
Sometimes the public just doesn’t appreciate a good thing. That anyway is the view of Danish payments company, Nets, which is recommending a $5.3 billion private-equity buyout offer barely a year after it listed.
While the debate goes on about how AIG should be treated by regulators, more significant changes are happening behind the scenes at the company
Unilever’s purchase of Carver Korea is the company’s biggest acquisition in seven years and among its most expensive, but the Seoul-based skin-care company give the Anglo-Dutch giant the kind of exposure it needs.
IDEAS DE INVERSION
on Thursday, 28 June 2012. Posted in Noticias_category(English)
DIVERSIFICACIÓN, ATRACTIVA VALORACIÓN Y GENERACIÓN DE INGRESOS ADAPTADOS A LA REALIDAD ECONÓMICA ACTUAL, SON ATRIBUTOS CONSIDERADOS POR EL COMITÉ DE RIESGO DE DAVOS FINANCIAL GROUP PARA EL SEGUNDO SEMESTRE DE 2012. IDEAS DE INVERSION A continuación detallamos las 7 ideas de inversión mas relevan [...]